Communications Biology (Dec 2022)
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
- Claudia Alteri,
- Valeria Fox,
- Rossana Scutari,
- Giulia Jole Burastero,
- Sara Volpi,
- Matteo Faltoni,
- Vanessa Fini,
- Annarita Granaglia,
- Sara Esperti,
- Altea Gallerani,
- Valentino Costabile,
- Beatrice Fontana,
- Erica Franceschini,
- Marianna Meschiari,
- Andrea Campana,
- Stefania Bernardi,
- Alberto Villani,
- Paola Bernaschi,
- Cristina Russo,
- Giovanni Guaraldi,
- Cristina Mussini,
- Carlo Federico Perno
Affiliations
- Claudia Alteri
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Valeria Fox
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Rossana Scutari
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Giulia Jole Burastero
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Sara Volpi
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Matteo Faltoni
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Vanessa Fini
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Annarita Granaglia
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Sara Esperti
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Altea Gallerani
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Valentino Costabile
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Beatrice Fontana
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Erica Franceschini
- Department of Infectious Diseases, AOU Modena
- Marianna Meschiari
- Department of Infectious Diseases, AOU Modena
- Andrea Campana
- Academic Department of Pediatrics, Bambino Gesù Children’s Hospital IRCCS
- Stefania Bernardi
- Academic Department of Pediatrics, Bambino Gesù Children’s Hospital IRCCS
- Alberto Villani
- Academic Department of Pediatrics, Bambino Gesù Children’s Hospital IRCCS
- Paola Bernaschi
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Cristina Russo
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- Giovanni Guaraldi
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Cristina Mussini
- Department of Infectious Diseases, University of Modena and Reggio Emilia
- Carlo Federico Perno
- Multimodal Research Area, Microbiology and Diagnostics of Immunology Unit, Bambino Gesù Children Hospital IRCCS
- DOI
- https://doi.org/10.1038/s42003-022-04322-8
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 12
Abstract
A proof-of-concept study on the genomic evolution of SARS-CoV-2 during antiviral treatment reveals that Molnupiravir induces a higher in vivo intra-host variability compared to Paxlovid and drug-naive.
